Opinions on drugs - Posted on Jan 24 2013
Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use.
The actual benefit of OZURDEX 700 μg intravitreal implant in applicator is substantial.
Clinical Added Value
OZURDEX 700 μg intravitreal implant in applicator offers a minor improvement in actual benefit (IAB IV) in the management of the treatment of macular oedema and oedema following either branch retinal vein occlusion or central retinal vein occlusion.
Évaluation des médicaments